FORFIVO XL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FORFIVO XL (FORFIVO XL).

How it works

FORFIVO XL (buprenorphine) is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic effects with a ceiling on respiratory depression. It also dissociates slowly from receptors, leading to a long duration of action and reduced withdrawal symptoms in opioid dependence.

What the body does with it

Metabolism	Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite). Norbuprenorphine is further metabolized by CYP2C8 and undergoes glucuronidation. Minor pathways: CYP2C9, CYP2C19, CYP2D6.
Excretion	Renal (30-40% as unchanged drug) and fecal (50-60% via biliary elimination as metabolites).
Half-life	Terminal elimination half-life of 10-12 hours in patients with normal renal function; prolonged to 18-24 hours in end-stage renal disease, requiring dose adjustment.
Protein binding	92-96% bound to albumin; binding is saturable at high concentrations.
Volume of Distribution	0.8-1.2 L/kg, indicating extensive distribution into tissues, with higher concentrations in liver, kidney, and gastrointestinal tract.
Bioavailability	Oral: 70-80% following first-pass metabolism; absolute bioavailability not determined due to lack of IV formulation. Food increases AUC by 15%.
Onset of Action	Oral: Peak plasma concentrations reached 1-2 hours after administration; pharmacodynamic effects observed within 2-4 hours.
Duration of Action	Approximately 12-24 hours based on twice-daily dosing; sustained trough levels maintain clinical effect over the dosing interval.

Classification & Brands

Dosing & administration

3 mg orally once daily for the first 2 weeks, then increase to 6 mg once daily; maximum 9 mg once daily.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR >=30 mL/min). Not recommended for severe renal impairment (eGFR <30 mL/min) due to lack of data.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50% (maximum 3 mg/day); Child-Pugh C: not recommended.
Pediatric use	Not approved in pediatric patients (<18 years) due to lack of safety and efficacy data.
Geriatric use	No specific dose adjustment; monitor renal function and adjust as needed; increased sensitivity may occur.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FORFIVO XL (FORFIVO XL).

Breastfeeding	Limited human data. Drug is excreted in human milk with an estimated M/P ratio of 0.6. Use with caution in breastfeeding infants, especially neonates and premature infants.
Teratogenic Risk	First trimester: No increased risk of major congenital malformations in human studies. Second and third trimesters: Risk of neonatal hypoglycemia and respiratory distress at birth if used near term. Avoid after 37 weeks gestation.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Warning: Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and risk of opioid analgesic overdose death with extended-release formulation.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; patients not already opioid-tolerant (for extended-release formulations used for pain); concurrent use of MAO inhibitors or use within 14 days.

Clinical Precautions

Precautions

Respiratory depression, particularly in patients with COPD or decreased respiratory reserve; CNS depression; risk of hypotension; hepatic impairment; adrenal insufficiency; severe injection site reactions (for implantable form); use in elderly, cachectic, or debilitated patients; use in patients with history of head injury or increased intracranial pressure; use in patients with biliary tract disease; risk of opioid-induced hyperalgesia; withdrawal upon abrupt discontinuation; risks of concurrent use with serotonergic drugs; increased risk of seizures; impaired driving or operating machinery.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

FORFIVO XL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for FORFIVO XL (FORFIVO XL).

How it works

What the body does with it

Metabolism	Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite). Norbuprenorphine is further metabolized by CYP2C8 and undergoes glucuronidation. Minor pathways: CYP2C9, CYP2C19, CYP2D6.
Excretion	Renal (30-40% as unchanged drug) and fecal (50-60% via biliary elimination as metabolites).
Half-life	Terminal elimination half-life of 10-12 hours in patients with normal renal function; prolonged to 18-24 hours in end-stage renal disease, requiring dose adjustment.
Protein binding	92-96% bound to albumin; binding is saturable at high concentrations.
Volume of Distribution	0.8-1.2 L/kg, indicating extensive distribution into tissues, with higher concentrations in liver, kidney, and gastrointestinal tract.
Bioavailability	Oral: 70-80% following first-pass metabolism; absolute bioavailability not determined due to lack of IV formulation. Food increases AUC by 15%.
Onset of Action	Oral: Peak plasma concentrations reached 1-2 hours after administration; pharmacodynamic effects observed within 2-4 hours.
Duration of Action	Approximately 12-24 hours based on twice-daily dosing; sustained trough levels maintain clinical effect over the dosing interval.

Classification & Brands

Dosing & administration

3 mg orally once daily for the first 2 weeks, then increase to 6 mg once daily; maximum 9 mg once daily.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (eGFR >=30 mL/min). Not recommended for severe renal impairment (eGFR <30 mL/min) due to lack of data.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50% (maximum 3 mg/day); Child-Pugh C: not recommended.
Pediatric use	Not approved in pediatric patients (<18 years) due to lack of safety and efficacy data.
Geriatric use	No specific dose adjustment; monitor renal function and adjust as needed; increased sensitivity may occur.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for FORFIVO XL (FORFIVO XL).

Breastfeeding	Limited human data. Drug is excreted in human milk with an estimated M/P ratio of 0.6. Use with caution in breastfeeding infants, especially neonates and premature infants.
Teratogenic Risk	First trimester: No increased risk of major congenital malformations in human studies. Second and third trimesters: Risk of neonatal hypoglycemia and respiratory distress at birth if used near term. Avoid after 37 weeks gestation.
Fetal Monitoring